(Press-News.org) Phase II study evaluates treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive blood cancer
The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) targets the CD123 antigen, which is overexpressed in BPDCN
PVEK monotherapy demonstrated strong responses, enabling ability to proceed with stem cell transplant for high-risk subgroup of patients with BPDCN
Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.
The findings were published today in the Journal of Clinical Oncology. The study was led by principal investigator and corresponding author Naveen Pemmaraju, M.D., professor of Leukemia, and senior author Naval Daver, M.D., professor of Leukemia.
“These strong, durable response results offer hope to BPDCN patients with limited treatment options,” Pemmaraju said. “An effective and safe frontline treatment for patients would be practice changing, and these positive results suggest that PVEK should be considered a potential standard treatment for BPDCN patients.”
Early data from the trial was presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. In addition, data was shared at the 2025 American Society of Clinical Oncology Annual Meeting.
What is BPDCN, and why is it difficult to treat?
BPDCN is a rare, aggressive blood cancer that affects multiple organs, including a patient’s skin, bone marrow and lymph nodes, which makes diagnosis and treatment complex. The disease is difficult to treat because of its hybrid nature, having elements of both lymphoid and myeloid malignancies, according to Pemmaraju. In addition, the disease can frequently mimic other related blood cancers or present alongside them.
The current standard of care for patients with BPDCN includes treatment with tagraxofusp-erzs, which targets CD123 found at high levels on certain cancer cells, including BPDCN. In 2018, researchers from MD Anderson led the clinical development to advance tagraxofusp-erzs toward Food and Drug Administration approval.
What is pivekimab sunirine?
PVEK is a next-generation CD123-targeted treatment. CD123 is overexpressed in the disease, leading to other therapeutic targets not working. PVEK delivers the therapeutic drug directly to cancer cells by targeting CD123 on the surface of BPDCN cells, resulting in rapid cancer cell death with limited targeting of healthy tissue.
What were the key findings of this study?
A total of 84 patients were treated as part of the trial. Of these, 33 patients received PVEK as a frontline treatment and 51 had relapsed or refractory disease. Eleven patients in the frontline treatment group had prior or concurrent cancer diagnoses in addition to BPDCN, making their treatment more complex and challenging.
For the frontline-treated patients, the overall response rate was 85%, and the median overall survival was 16.6 months. Eight of these patients proceeded to a stem-cell transplant, which is the only established curative option for BPDCN and is generally associated with improved survival in BPDCN. Patients with relapsed or refractory disease had an overall response rate of 35% and a median overall survival of 5.8 months.
Side effects were manageable overall, including peripheral edema and infusion-related reactions. The study’s overall efficacy suggests that PVEK could offer a valuable new option for patients with difficult-to-treat BPDCN.
Researchers at MD Anderson also are investigating the use of PVEK in combination approaches to treat frontline acute myeloid leukemia (AML).
“We are encouraged by what we are seeing in the treatment of BPDCN, and early results also indicate encouraging efficacy in frontline AML, including in combination approaches, as presented at the 2025 ASH Annual Meeting,” Daver said.
***
This research was supported by AbbVie. For a full list of collaborating authors, disclosures and funding sources, see the full paper in the Journal of Clinical Oncology.
END
Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
2026-02-11
ELSE PRESS RELEASES FROM THIS DATE:
Retina-inspired cascaded van der Waals heterostructures for photoelectric-ion neuromorphic computing
2026-02-11
Professor Zhen Zhang's research group at the State Key Laboratory of Bionic Interface Materials Science, University of Science and Technology of China, proposed and constructed a neuromorphic computing system based on a cascaded van der Waals heterostructure two-dimensional nanofluidic membrane, achieving light-driven electron-ion coupling to simulate neural signal transmission and neuromorphic visual information processing. The article was published as an open access Research Article in CCS Chemistry, the flagship journal of the Chinese ...
Seashells and coconut char: A coastal recipe for super-compost
2026-02-11
In the lush landscapes of tropical agriculture, two waste products—oyster shells from the sea and coconut shells from the trees—are being combined to solve a major headache for farmers: how to turn animal manure into high-quality compost faster and more effectively. A study recently published in Carbon Research reveals that a unique "Ca-modified biochar" can act as a powerful catalyst for the composting process. Developed by a research team at Hainan University, this new material helps transform pig manure and rice straw into stable, nutrient-rich humus, significantly boosting the ...
Feeding biochar to cattle may help lock carbon in soil and cut agricultural emissions
2026-02-11
Researchers have found that most biochar fed to dairy cows survives the digestive process and remains highly stable, meaning it could be applied to fields through manure and act as a long-term carbon storage solution. The findings provide new evidence that livestock systems could play a role in climate change mitigation.
The study, recently published in Biochar, investigated what happens to biochar after it passes through the digestive system of cattle. Biochar is a carbon-rich material produced ...
Researchers identify best strategies to cut air pollution and improve fertilizer quality during composting
2026-02-11
Scientists have uncovered practical strategies that can significantly reduce harmful air pollution from composting while improving the quality of organic fertilizers. The findings, based on a large global meta-analysis, provide new evidence to help farmers, waste managers, and policymakers adopt climate-smart composting practices.
The research, published in Environmental and Biogeochemical Processes, analyzed data from 135 scientific studies and 1,683 experimental observations worldwide. The study evaluated how different ...
International research team solves mystery behind rare clotting after adenoviral vaccines or natural adenovirus infection
2026-02-11
A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and Universitätsmedizin Greifswald (Germany) uncovered why a small number of people developed dangerous blood clots after either receiving certain COVID‑19 vaccines or experiencing a natural adenovirus infection, and the answer lies in an unexpected case of misdirected targeting by the immune system.
The discovery, published Feb. 12, 2026 in the New England Journal of Medicine, explains ...
The most common causes of maternal death may surprise you
2026-02-11
NEW YORK, NY--Researchers at Columbia University have found that accidental drug overdose, homicide, and suicide are the leading causes of death among pregnant and postpartum women.
The findings were published in the New England Journal of Medicine.
“Overdose and violence are not typically on our radar when it comes to thinking about approaches to reducing maternal morbidity and mortality, but these events are far more common among pregnant and postpartum women than we think,” says Hooman Azad, who led the study and is a maternal-fetal medicine fellow ...
A new roadmap spotlights aging as key to advancing research in Parkinson’s disease
2026-02-11
Even though aging is the largest risk factor for Parkinson’s disease, the majority of research aimed at taming the incurable neurodegenerative motor disease has largely left aging out of the mix. A group of researchers from around the globe seek to change that. “Unraveling the intersection of aging and Parkinson’s disease: a collaborative road map for advancing research models,” is now available online at the Nature publication npj Parkinson’s Disease.
The vast majority ...
Research alert: Airborne toxins trigger a unique form of chronic sinus disease in veterans
2026-02-11
Researchers at the University of California San Diego and the Veterans Affairs San Diego Healthcare System have identified a distinct biological pattern of chronic rhinosinusitis (CRS), a chronic respiratory illness frequently associated with exposure to airborne toxins, such as wildfire smoke and military burn pits. The research team, led by first author and UC San Diego Assistant Professor of Medicine Xinyu "Steve" Wang, MD, PhD, found that veterans with CRS who were exposed to burn pits and other toxins show a marked increase in sinus ...
University of Houston professor elected to National Academy of Engineering
2026-02-11
University of Houston engineering professor Venkat Selvamanickam has been elected to the National Academy of Engineering, one of the highest professional honors awarded to engineers worldwide.
Selvamanickam is the M.D. Anderson Chair Professor of Mechanical & Aerospace Engineering and director of the Advanced Manufacturing Institute at the UH Cullen College of Engineering. He was recognized for his cutting-edge contributions to industrial-scale advanced manufacturing processes for high-temperature superconductor wires ...
UVM develops new framework to transform national flood prediction
2026-02-11
When severe weather strikes, the National Weather Service’s (NWS) Office of Water Prediction (OWP) makes critical flood forecasts with the National Water Model. Despite improvements over time, the model’s performance has plateaued in recent years, leaving researchers from the federal government, academia, and private industry searching for a better solution.
Now a new set of software tools, the Next Generation Water Resources Modeling framework, or NextGen, will help develop better predictions. As detailed in a new study led by OWP and the University ...